MedTrace Logo

A Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia

NCT07255846 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2026-04-13

No results posted yet for this study

Summary

This is a Phase 1a/1b, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of TER-1754 (a novel AKT1 inhibitor) in patients with HHT.

Conditions

  • Hereditary Hemorrhagic Telangiectasia (HHT)

Interventions

DRUG

TER-1754

QD or BID, orally in 28-day cycles

DRUG

Placebo

Number of tablets will be confirmed post Phase 1a

DRUG

TER-1754

Phase 1b dose to be determined post Phase 1a

Sponsors & Collaborators

  • Terremoto Biosciences Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-15
Primary Completion
2028-03-31
Completion
2028-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07255846 on ClinicalTrials.gov